* chronic statin use, serum creatine kinase (sr ck) \> 5 times the upper limit of normal (uln), serum transaminases \> 5 times uln, acute hepatic failure, chronic liver disease (child-pugh classification c), history of rhabdomyolysis or myopathies, severe renal impairment not receiving renal replacement therapy (estimated cr cl\< 30 ml\\min ), pregnant and lactating women, patients who are expected to die within 48 hours, or patients on chronic colchicine, cyclosporines, or ritonavir.

* chronic statin use, serum creatine kinase (sr ck) \> 5 times the upper limit of normal (uln), serum transaminases \> 5 times uln, acute hepatic failure, chronic liver disease (child-pugh classification c), history of rhabdomyolysis or myopathies, severe renal impairment not receiving renal replacement therapy (estimated cr cl\< 30 ml\\min ), pregnant and lactating women, patients who are expected to die within 48 hours, or patients on chronic colchicine, cyclosporines, or ritonavir.

- chronic statin use, serum creatine kinase (sr ck) > 5 times the upper limit of normal (uln), serum transaminases > 5 times uln, acute hepatic failure, chronic liver disease (child-pugh classification c), history of rhabdomyolysis or myopathies, severe renal impairment not receiving renal replacement therapy (estimated cr cl< 30 ml\min ), pregnant and lactating women, patients who are expected to die within 48 hours, or patients on chronic colchicine, cyclosporines, or ritonavir.

- chronic statin use, serum creatine kinase (sr ck) > 5 times the upper limit of normal (uln), serum transaminases > 5 times uln, acute hepatic failure, chronic liver disease (child-pugh classification c), history of rhabdomyolysis or myopathies, severe renal impairment not receiving renal replacement therapy (estimated cr cl< 30 ml\min ), pregnant and lactating women, patients who are expected to die within 48 hours, or patients on chronic colchicine, cyclosporines, or ritonavir.